Clinical Trial: Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT04712903) titled 'Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer' on Dec. 3, 2020.

Brief Summary: This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with platinum-etoposide as first-line treatment in Spain.

Study Type: Interventional

Condition: Small Cell Lung Carcinoma Extensive Disease

Intervention: * Drug: Durvalumab

Durvalumab 1500 mg via IV infusion on Day 1 of each cycle.

* Drug: Cisplatin

Cisplatin as an IV infusion over 60 minut...